IP Library › Granted Patent US 7,834,163
Granted Patent B2
US 7,834,163 · App. 10/560,723 · Granted Nov 16, 2010

Prostate specific genes and the use thereof as targets for prostate cancer therapy

Assignee: Exonhit Therapeutics S.A.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,834,163
App. No.
10/560,723
Granted
Nov 16, 2010
Kind
B2
Abstract

Genes that are upregulated in human prostate tumor tissues and the corresponding proteins are identified. These genes and the corresponding antigens are suitable targets for the treatment, diagnosis or prophylaxis of prostate cancer.

Claims (5)

1. An isolated nucleic acid that is expressed by human prostate cancer cells, wherein said nucleic acid comprises the sequence of SEQ ID NO: 92.

2. A diagnostic kit for detection of prostate cancer which comprises a nucleic acid according to claim 1 and a detectable label.

3. An isolated nucleic acid component comprising a detectable label and a nucleic acid sequence comprising the sequence of SEQ ID NO: 92.

4. The nucleic acid component of claim 3 wherein said detectable label is selected from the group consisting of an indicator enzyme, a radiolabel, a fluorophore and a paramagnetic particle.

5. The kit of claim 2 wherein said detectable label is selected from the group consisting of an indicator enzyme, a radiolabel, a fluorophore and a paramagnetic particle.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 15, 2006
From: EINSTEIN, RICHARD; MCGOWAN, KEVIN M.; PANDO, MATTHEW P.
To: EXONHIT THERAPEUTICS S.A.
Reel/Frame 018003/0735 →
Continuity (2)
Provisional Application 6048259500 · Jun 26, 2003
Related Publication 20060115821A1 · Jun 1, 2006